Feline Cardiogenic Arterial Thromboembolism: Prevention and Therapy

Daniel F Hogan1

  • 1Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, Lynn Hall, 625 Harrison Street, West Lafayette, IN 47907-2026, USA.

Insights

Feline cardiogenic arterial thromboembolism (CATE) is a severe condition in cats. Clopidogrel is more effective than aspirin for preventing CATE recurrence, offering a better long-term outcome.

Area of Science:

  • Veterinary Cardiology
  • Thrombotic Disease Research
  • Feline Medicine

Background:

  • Feline cardiogenic arterial thromboembolism (CATE) is a critical condition with high mortality.
  • A significant portion of CATE mortality results from euthanasia.
  • Current management involves inducing a hypocoagulable state and supportive care.

Purpose of the Study:

  • To evaluate management strategies for feline cardiogenic arterial thromboembolism.
  • To compare the efficacy of different preventive protocols for CATE.
  • To assess the long-term outcomes of CATE management in cats.

Main Methods:

  • Review of short-term management focusing on hypocoagulability and blood flow.
  • Analysis of preventive protocols, including antiplatelet and anticoagulant drugs.
  • Examination of data from the only prospective clinical trial comparing clopidogrel and aspirin.

Main Results:

  • Clopidogrel demonstrated superiority over aspirin in a prospective clinical trial.
  • Clopidogrel was associated with a lower CATE recurrence rate.
  • Cats treated with clopidogrel experienced a longer time to recurrent CATE.

Conclusions:

  • Clopidogrel is a superior preventive treatment for feline cardiogenic arterial thromboembolism compared to aspirin.
  • Optimal management includes a 72-hour treatment window to determine the acute clinical course.
  • Emerging anticoagulant drugs show potential for future CATE management.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
423
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
542
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
343
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
667
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
516
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
266